<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJIM</journal-id><journal-title-group><journal-title>Open Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="epub">2162-5972</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojim.2018.82012</article-id><article-id pub-id-type="publisher-id">OJIM-83558</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Epidemiological, Clinical and Paraclinical Aspects of Cirrhosis at Borgou Departmental University Hospital Center (Benin)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Comlan</surname><given-names>Albert Dovonou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cossi</surname><given-names>Adébayo Alassani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kadidjatou</surname><given-names>Sake</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cossi</surname><given-names>Angelo Attinsounon</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Angèle</surname><given-names>Azon-Kouanou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Agossou</surname><given-names>Romaric Tandjiekpon</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djimon</surname><given-names>Marcel Zannou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fabien</surname><given-names>Houngbe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Medicine Department and Medical Specialities of Cotonou Health and Science Faculty, Cotonou, Benin</addr-line></aff><aff id="aff2"><addr-line>Internal Medicine Department, Departmental Hospital Center of Borgou, Parakou, Benin</addr-line></aff><aff id="aff1"><addr-line>Medicine Department and Medical Specialities, Medical Faculty, Parakou University, Parakou, Benin</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>dovcom1@yahoo.fr(CAA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>04</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>113</fpage><lpage>122</lpage><history><date date-type="received"><day>12,</day>	<month>February</month>	<year>2018</year></date><date date-type="rev-recd"><day>31,</day>	<month>March</month>	<year>2018</year>	</date><date date-type="accepted"><day>3,</day>	<month>April</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Objective:</b> To study the epidemiological, clinical and paraclinical aspects of cirrhosis at Borgou Departmental University hospital Center. 
  <b>Methods:</b> This is a retrospective study for descriptive purpose conducted in the Internal Medicine Department. The study population consists of patients hospitalized in the Internal Medicine Department during the period from 1st January 2009 to 31st December 2016. 
  <b>Results:</b> The frequency of cirrhosis was 1.35%. The sex ratio was 3.76. The average age of patients was 45.22 &#177; 15.23 years old, with a range from 15 to 82 years. There is a post hepatitis Bcirrhosis predominance in 87.5% of cases, followed by alcoholic cirrhosis in 21.59% of cases. The complications of cirrhosis are dominated by ascites (78.4%) and jaundice (52%). 
  <b>Conclusion:</b> Cirrhosis is a condition that is wide spread. The hepatitis B virusis the main cause of liver cirrhosis followed by alcoholism. Ascites is the most encountered complication. It’s very important now to educate the populations for a behaviour change and to promote vaccination against viral hepatitis.
 
</p></abstract><kwd-group><kwd>Epidemiology</kwd><kwd> Hepatic Cirrhosis</kwd><kwd> Parakou</kwd><kwd> Benin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Hepatic cirrhosis is a pathology characterized by the disorganization of liver architecture attributable to hepatocytes destruction since the hepatocellular regeneration remains in form of regeneration nodules with the presence of fibrosis. Nowadays, it’s a public health problem [<xref ref-type="bibr" rid="scirp.83558-ref1">1</xref>] . The real world prevalence of hepatic cirrhosis is not well known but can exceed 1% if a liver biopsy and anatomopathological examination are realized for the benefit of the general population. In United State, Cirrhosis prevalence is 0.15% and represents respectively the tenth and the twelfth cause of death in men and in women, killing about 35,000 people every year [<xref ref-type="bibr" rid="scirp.83558-ref2">2</xref>] . In Europe, almost 170,000 of death related to cirrhosis are registered per year and represent 1.8% of all causes of death [<xref ref-type="bibr" rid="scirp.83558-ref3">3</xref>] . In Africa, the hospital prevalence of cirrhosis is at 7.02% in 2012 in Togo [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] and 2.35% in 2008 in Mali [<xref ref-type="bibr" rid="scirp.83558-ref5">5</xref>] . In Cotonou (Benin), S&#232;honou et al. have reported 22.6% as prevalence in 2006; Viral hepatitis Band chronic alcoholism are the most frequent reported causes [<xref ref-type="bibr" rid="scirp.83558-ref6">6</xref>] . No studies on hepatic cirrhosis have been performed in northern Benin. The present study was initiated to identify the different and the most common cause of hepatic cirrhosis. The results of this study will help prevent liver cirrhosis. The goal of this study is to describe the epidemiological, clinical and paraclinical aspects of cirrhosis in Borgou Departmental University hospital Center.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>This is a retrospective study for a descriptive purpose conducted in the Internal Medicine Department. The study population consists of the patients hospitalized in the Internal Medicine Department from 1 St January 2009 to 31 St December 2016. We included only the patients with liver cirrhosis. Diagnostic criteria used for the diagnosis of liver cirrhosis were as follows:</p><p>- Signs in accordance with cirrhosis in the laboratory analyses: AST/ALT ratio &gt; 1, presence of thrombocytopenia, and prolonged prothrombin time.</p><p>- Imaging findings (ultrasonography and/or tomography): decrease in the liver size, parenchymal heterogeneity, superficial nodular changes, hypertrophy of the left lobe, splenomegaly and dilatation of portal vein.</p><p>- Clinical and endoscopic signs suggestive of cirrhosis; splenomegaly, esophageal varices, ascites, hepatic encephalopathy.</p><p>The study variables are:</p><p>- Epidemiological Data</p><p>• Frequency of liver cirrhosis. The diagnosis of cirrhosis is decided based on clinical and paraclinical arguments. Liver biopsy and anatomopathological examination were not done due to the lack of technical capacity means.</p><p>• Age of the patients</p><p>• The sex</p><p>- Clinical Data</p><p>• Functional signs</p><p>• History</p><p>• General signs</p><p>• Physical signs</p><p>- Paraclinical Data</p><p>• Liver function tests</p><p>• Liver morphology explorations</p><p>The analysis has been done using the software Epi Data, version 3.1.</p><p>This study has used the data of a retrospective cohort. Neither the names nor others characteristics allowing the patients recognition were collected. The agreement of the National Ethics Committee for Health Research http://www.ethique-sante.org/) according to the recommendations was not requireddue to its retrospective character.</p></sec><sec id="s3"><title>3. Results</title><p>Epidemiological Data</p><p>Out of 9260 patients who consulted or have been hospitalized in the Internal Medicine Department, 125 suffered from hepatic cirrhosis or a frequency at 1.35%.</p><p>Among the cirrhotic patients, a male predominance has been noticed: 99 men for 26 women. The sex ratio was 3.76.</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows cirrhotic patients distribution by age. The average age of the patients was 45.22 &#177; 15.23 years, with the extremes 15 and 82 years of age. About 8 out 10 patients were between the ages of 25 and 64 years old.</p><p>Clinical characteristics</p><p>➢ Consultation period: All the patients were seen at a late phase with complications. The average period of consultation was 4.45 &#177; 1.2 months with the extremes 1 and 48 months; 60% of patients consulted three months after the first signs of decompensation.</p><p>➢ Reason for consultation: dominated by abdominal pain (56.8%), fever (43.2%) and right hypochondrium lump (40%).</p><p>➢ Patient’s history: Dominated by jaundice (36.8%), alcoholism (29.6%) and smoking (29.6%).</p><p>➢ The examination of the general condition found asthenia (83.2%), weight loss (78.4%), anorexia (70.4%) and fever (37.6%).</p><p>➢ The physical signs were dominated by ascites (78.4%), hepatomegaly (66.88%) lower limb oedema (63.2%). <xref ref-type="table" rid="table1">Table 1</xref> shows the different signs found during the physical exam.</p><p>Ascitic fluid examination</p><p>➢ Ascitic fluid was macroscopically yellow citrine (89.6%), hemorrhagic (8.6%) or cloudy (1.6%).</p><p>➢ Cytobacteriological examination of the fluid showed a leukocyte count lower than 250/mm<sup>3</sup> in 96.8% of the cases.</p><p><xref ref-type="table" rid="table2">Table 2</xref> points out the results of the ascitic fluid examination.</p><p>Paraclinical characteristics</p><p>➢ Liver function tests</p><p>• The average level of prothrombin was 51.85% &#177; 5.7%.</p><p>• The average level of AST (Aspartate Aminotransferase) was 189.13 &#177; 24.02 UI/L and the one of ALT (Alanine Aminotransferase) was 87.98 &#177; 17.15 UI/L. The ratio AST/ALT ≥ 1 in 92.1% of cases.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Physical signs found in 125 cirrhotic patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Ascites</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >78.40</td></tr><tr><td align="center" valign="middle" >Lower limbs oedema</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >63.20</td></tr><tr><td align="center" valign="middle" >Clinical anemia</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >59.20</td></tr><tr><td align="center" valign="middle" >Jaundice</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >52</td></tr><tr><td align="center" valign="middle" >Hepatomegaly</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >68.88</td></tr><tr><td align="center" valign="middle" >Normal or atrophic liver</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >31.12</td></tr><tr><td align="center" valign="middle" >Splenomegaly</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >Collateral venous circulation</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >40</td></tr><tr><td align="center" valign="middle" >Pleurisy</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4.80</td></tr><tr><td align="center" valign="middle" >Scarification</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >3.20</td></tr><tr><td align="center" valign="middle" >Flapping tremor</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8.80</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Results of the ascites fluid examination in 125 cirrhotic patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Macroscopic aspects</td></tr><tr><td align="center" valign="middle" >Citrine</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >89.6</td></tr><tr><td align="center" valign="middle" >Hemorrhagic</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >8.8</td></tr><tr><td align="center" valign="middle" >Cloudy</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.6</td></tr><tr><td align="center" valign="middle"  colspan="3"  >White blood cells count</td></tr><tr><td align="center" valign="middle" >&lt;250/mm<sup>3</sup></td><td align="center" valign="middle" >121</td><td align="center" valign="middle" >96.8</td></tr><tr><td align="center" valign="middle" >≥250/mm<sup>3</sup></td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3.2</td></tr></tbody></table></table-wrap><p>• The average value of totalbilirubinemia was 77.82 &#177; 14.6 mg/L and varied from 1 to 498 mg/L.</p><p>• The level of Gamma Glutamyl Transferase (GGT) varied from 39 to 3024 UI/L with an average level at 413 &#177; 33 UI/L.</p><p>• The average level of alkaline phosphatase was 473.44 &#177; 24.89 UI/L and varied from 138 to 1000 UI/L.</p><p>➢ The abdominal ultrasound focused on liver realized in 105 patients showed:</p><p>• The average size of the liver was 150.47 &#177; 46.15 mm and varied between 50 and 250 mm.</p><p>• The average size of the spleen was 156.10 &#177; 41.11 mm and varied from 80 to 251 mm. 56.38% of patients had a splenomegaly.</p><p>• The average diameter of the portal vein was 15.87 &#177; 2.27 mm with 21 mm as maximum.</p><p><xref ref-type="table" rid="table3">Table 3</xref> shows the observed signs by the abdominal ultrasonography.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Results of abdominal ultrasonography in 105 cirrhotic patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Size</td></tr><tr><td align="center" valign="middle" >Hepatomegaly</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >65.71</td></tr><tr><td align="center" valign="middle" >Normal or atrophic liver</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >34.29</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Contour</td></tr><tr><td align="center" valign="middle" >Regular</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Irregular</td><td align="center" valign="middle" >105</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Homogeneity</td></tr><tr><td align="center" valign="middle" >Heterogeneous</td><td align="center" valign="middle" >105</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Homogeneous</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Nodular aspect</td></tr><tr><td align="center" valign="middle" >Micronodular</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >47.61</td></tr><tr><td align="center" valign="middle" >Macronodular</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >44.76</td></tr><tr><td align="center" valign="middle" >Mixed</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >7.61</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Dilatation of portal vein</td></tr><tr><td align="center" valign="middle" >&lt;13 mm</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >32.38</td></tr><tr><td align="center" valign="middle" >≥13 mm</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >67.62</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Splenomegaly</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >55.23</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >44.77</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Ascites</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >80</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >20</td></tr></tbody></table></table-wrap><p>➢ The etiology of cirrhosis has been identified in 87 cases with a predominance of post hepatitis B cirrhosis in 68 cases (87.5%) followed by alcoholic liver cirrhosis in 11 cases (21.59%). <xref ref-type="fig" rid="fig2">Figure 2</xref> shows the etiologies of cirrhosis.</p><p>➢ The complications of cirrhosis are dominated by ascites (78.4%) and jaundice (52%). <xref ref-type="table" rid="table4">Table 4</xref> shows the complications of cirrhosis.</p></sec><sec id="s4"><title>4. Discussion</title><p>The frequency of cirrhosis in Internal Medicine Department of Borgou Departmental University hospital Center was 1.35%. The prevalence of cirrhosis is extremely variable from one country to another and from one continent to another. In West Africa S&#232;honou et al. in 2006 [<xref ref-type="bibr" rid="scirp.83558-ref6">6</xref>] have reported 22.60% as frequency in Internal Medicine Department of National Teaching Hospital in Cotonou; Bouglouga et al. in 2012 [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] have reported a prevalence at 7.02% in Togo. The frequency of cirrhosis at 1.35% in Borgou Departmental University</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Complications encountered in 125 cirrhotic patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >N</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >Ascites</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >78.40</td></tr><tr><td align="center" valign="middle" >Lower limbs oedema</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >63.20</td></tr><tr><td align="center" valign="middle" >Ascitesandoedema</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >57.60</td></tr><tr><td align="center" valign="middle" >Jaundice</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >52</td></tr><tr><td align="center" valign="middle" >Carcinoma</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >51.20</td></tr><tr><td align="center" valign="middle" >Biological anemia</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >43.20</td></tr><tr><td align="center" valign="middle" >Infection</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >40.80</td></tr><tr><td align="center" valign="middle" >Digestive hemorrhage</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >Kidney failure</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >19.20</td></tr><tr><td align="center" valign="middle" >Hepatic encephalopathy</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >10.40</td></tr></tbody></table></table-wrap><p>hospital Center is lower than the one at 22.60% reported by S&#232;honou et al. at National Teaching Hospitalin Cotonou. In reality, the prevalence reported by S&#232;honou et al. was the one of hepatitis cirrhosis at the hepatogastroenterology department that usually receives patients suffering from digestive pathologies like chronic hepatopathies. The Internal Medicine Department of Borgou Departmental University hospital Centerreceives patients coming from all the medical specialities.</p><p>Among the 125 cirrhotic patients of our series, there were 99 men and 26 women with a sex ratio at 3.76. Many studies have reported a male predominance; the sex ratio varies between 1.38 and 4.6 [<xref ref-type="bibr" rid="scirp.83558-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref9">9</xref>] . Where as Houissa et al., reported a female predominance with a sex ratio at 0.83 [<xref ref-type="bibr" rid="scirp.83558-ref10">10</xref>] .</p><p>The average age of our patients was 45.22 &#177; 15.23 years. That was similar to the one reported by many authors notably S&#232;honou et al. (49 years of age) and Ouavene et al. (45 years) [<xref ref-type="bibr" rid="scirp.83558-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] . In Turkey, en Greece and Romania, the average age of the cirrhotic patients was higher. Those authors have respectively reported 55.3 years, 56 years and 59 years [<xref ref-type="bibr" rid="scirp.83558-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref14">14</xref>] . That higher average age could be explained by the exposure to the hepatitis B virus (HBV) which was the main cause of cirrhosis in childhood in developing countries like Benin and also the absence of vaccination against that virus. Mother-to-child transmission is a real source of infection. This is augmented by unprotected sex mostly for teenagers.</p><p>All the patients were seen at a phase of decompensation, the average period for consultation was 4.45 months. In Togo, that has been observed by Bouglouga et al. who reported that 78.1% of patients consulted one year after the progression of the disease [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] .</p><p>Among the patients history, jaundice and alcoholism account for respectively 36.80% and 29.60% of cases. According to the study of Ouavene et al., 63.5% had jaundice as history and 34% are chronic alcoholics [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] .</p><p>Most of the patients had a poor general condition with asthenia (83%) and loss of weight (78%). The cirrhotic patients were undernourished. The prevalence of under nutrition during cirrhosis is approximately 50% at all the stages of the disease. That under nutrition is due to the reduction of food intake, a malabsorption and a hypercatabolism. The cirrhotic patient doesn’t eat much since he is still anorexic, nauseous, with an altered sense of taste and a feeling of gastric fullness. According to the study of Xie et al., 56.6% of the patients were asthenic and 34.1% were anorexic [<xref ref-type="bibr" rid="scirp.83558-ref15">15</xref>] . Hepatomegaly was found in 68.8% of cases, ascites (78.40%) andsplenomegaly (56%), collateral venous circulation (40%) and abdominal pain (56.80%). Hepatomegaly was the main morphological change reported by the authors [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.83558-ref6">6</xref>] . Aboutsplenomegaly and collateral venous, Bouglouga et al. [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] have respectively reported 13% and 5.2% and Ouavene et al. reported [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] 77.50% and 95.50%.</p><p>Hepatic ultrasonography realized showed hepatomegaly in 65.71% of cases. In the series of Ouavene et al. [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] , hepatomegaly accounted for only 30% whereas the liver size was normal in 67.5% of cases.</p><p>The analysis of the ascitic fluid revealed a leukocyte count inferior to 250/mm<sup>3</sup> in 96.8% of cases, or an absence of infection encountered in most of non-complicated hepatic cirrhosis [<xref ref-type="bibr" rid="scirp.83558-ref16">16</xref>] . Ouavene et al. have reported a yellow citrineascitic fluid (82%) with a negative Rivalta’s test results (76.7%) [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] . In this study, the average level of prothrombin was 51.85% reflecting a hepatocellular insufficiency. In Togo, Bouglouga et al. have reported a decrease in the level of prothrombin at 70% in 85.5% of cases [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] .</p><p>The average value of AST was 189.13 UI/L and the one of ALT was 87.98 UI/L with the ratio ASAT/ALAT ≥ 1 in 92.1% of cases. Ouavene et al. reported a cytolysis in 71.50% of cases for the AST and 68% for the ALT [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] . Xie et al. have also reported a predominant hepatic cytolysis for the AST with a ratio AST/ALT at 2.00 &#177; 1.20 [<xref ref-type="bibr" rid="scirp.83558-ref15">15</xref>] .</p><p>The average level of total bilirubinemia was 77.82 mg/L, the one of Gamma GT was 413 UI/L and 473.44 UI/L for alkaline phosphatase witness of cholestasis. In their series, over half of the patients suffered from cholestasis according to Ouavene et al. [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] .</p><p>In this study, hepatitis B virus is the main cause of hepatic cirrhosis (87.5%) followed by chronic alcoholism (21.59%). That predominance of post hepatitis B cirrhosis has been pointed out by Topdagi et al. who reported hepatitis B as the major cause of hepatic cirrhosis in the developing countries [<xref ref-type="bibr" rid="scirp.83558-ref12">12</xref>] . Post hepatitis cirrhosis are the most represented (54.5%) followed by alcoholic cirrhosis (32.5%) according to Ouavene et al. [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] . In his study conducted in Turkey, 52% of hepatic cirrhosis were due to hepatitis B virus; Alcohol were found in 2% of cases. The low proportion of alcoholic cirrhosis could be explained by the low alcohol consumption in Muslim countries like Turkey. In Tunisia, viral causes (75%) and mostly hepatitis C virus (62.5%) have been reported as the main causes of hepatic cirrhosis. In developed countries, it’s rather alcohol and hepatitis C virus the main causes of hepatic cirrhosis [<xref ref-type="bibr" rid="scirp.83558-ref17">17</xref>] . In Germany, alcohol is responsible of hepatic cirrhosis for 52% followed by hepatitis C virus (28%) and hepatitis B virus (14%) [<xref ref-type="bibr" rid="scirp.83558-ref18">18</xref>] . Hepatic cirrhosis inescapably progresses to the complications [<xref ref-type="bibr" rid="scirp.83558-ref11">11</xref>] . In this study, many complications have been identified. Among these, ascites was observed in 78.40%, hepatocellular carcinoma 51.20%, jaundice 52%, and infections 40.8%.Similar results have been reported by many authors. Bouglouga et al. [<xref ref-type="bibr" rid="scirp.83558-ref4">4</xref>] have reported some complications like ascites, hepatocellular carcinoma and hepatic encephalopathy in respectively 60%, 26.3% and 7.5% of cases. Among the complications reported by Topdagi et al., there is an ascites predominance (83%) followed by digestive hemorrhage (56%), Peritonitis (42%), hepatic encephalopathy (26%) [<xref ref-type="bibr" rid="scirp.83558-ref12">12</xref>] . Xie et al. [<xref ref-type="bibr" rid="scirp.83558-ref15">15</xref>] and Bruno et al. [<xref ref-type="bibr" rid="scirp.83558-ref18">18</xref>] have reported an ascites predominance in respectively 60% and 76.65% of cases.</p><p>Esophageal varices have been observed in 60% of cases and ascites in 49 % according to Kittner et al. [<xref ref-type="bibr" rid="scirp.83558-ref19">19</xref>] .</p><p>This study has limits cause of limit number of patients and the type of study. Another study on a grand scale and cross sectional study would be necessary.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Hepatic cirrhosis is a growing pathology. Hepatitis B virus is the main cause of hepatic cirrhosis followed by chronic alcoholism. Vaccination against hepatitis B virus and a decrease in alcoholic consumption are necessary in order to reduce the incidence of hepatic cirrhosis. That vaccination against hepatitis B virus is necessary from childhood especially in our developing countries.</p></sec><sec id="s6"><title>Cite this paper</title><p>Dovonou, C.A., Alassani, C.A., Sake, K., Attinsounon, C.A., Azon-Kouanou, A., Tandjiekpon, A.R., Zannou, D.M. and Houngbe, F. (2018) Epidemiological, Clinical and Paraclinical Aspects of Cirrhosis at Borgou Departmental University Hospital Center (Benin). Open Journal of Internal Medicine, 8, 113-122. https://doi.org/10.4236/ojim.2018.82012</p></sec></body><back><ref-list><title>References</title><ref id="scirp.83558-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ouavene, J.O., Koffi, B., Mobima, T., Bekondji, C., Massengue, A. and Guenebem, A.K. (2014) Cirrhoses du foie à l’hopital de l’amitié de Bangui aspects épidémiologiques, cliniques, échographiques et problèmes de diagnostic. Journal African d’Imagerie Médicale, 5, 1-12.</mixed-citation></ref><ref id="scirp.83558-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mokdad, A.A., Lopez, A.D., Shahraz, S., Lozano, R., Mokdad, A.H., Stanaway, J., et al. (2014) Liver Cirrhosis Mortality in 187 Countries between 1980 and 2010: A Systematic Analysis. BMC Medicine, 12, 145.</mixed-citation></ref><ref id="scirp.83558-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Balkan, A., Alkan, S., Barutcu, S., Konduk, B.T., Yildirim, A.E. and Erdem, R. (2016) Etiological Distribution and Clinical Features of Cirrhotic Patients: Single Tertiary Referral Center Experience. Acta Medica Mediterranea, 32, 669-675.</mixed-citation></ref><ref id="scirp.83558-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Verhelst, X., Geerts, A. and Vlierberghe, H.V. (2017) Cirrhosis: Reviewing the Literature and the Future Perspectives. European Medical Journal, 1, 111-117.</mixed-citation></ref><ref id="scirp.83558-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bouglouga, O., Bagny, A. and Djibril, M. (2012) Aspects épidémiologiques, diagnostiques et évolutifs de la cirrhose hépatique dans le service d’hépato-gastroentérologie du chu campus de Lomé. J. Rech. Sci. Univ. Lomé (Togo), Série D, 14, 1-7.</mixed-citation></ref><ref id="scirp.83558-ref6"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diarra</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Konaté</surname><given-names> A. and Soukho </given-names></name>,<etal>et al</etal>. (<year>2010</year>)<article-title>Aspects évolutifs de la maladie cirrhotique dans un service d’hépato-gastroentérologie au mali</article-title><source> Mali Médical</source><volume> 14</volume>,<fpage> 42</fpage>-<lpage>46</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.83558-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sèhonou, J., Kodjoh, N., Saké, K. and Mouala, C. (2010) Cirrhose hépatique à Cotonou: Facteurs liés au décès. Médecinetropicale, 70, 375-378.</mixed-citation></ref><ref id="scirp.83558-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Mohammed, S., Abdo, A. and Mudawi, H. (2016) Mortality and Rebleeding Following Variceal Haemorrhage in Liver Cirrhosis and Periportal Fibrosis. World Journal of Hepatology, 8, 1336-1342. https://doi.org/10.4254/wjh.v8.i31.1336</mixed-citation></ref><ref id="scirp.83558-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mathur, A., Chakrabarti, A., Mellinger, J., Volk, M., Day, R. and Singer, A. (2017) Hospital Resource Intensity and Cirrhosis Mortality in United States. World Journal of Gastroenterology, 23, 1857-1865. https://doi.org/10.3748/wjg.v23.i10.1857</mixed-citation></ref><ref id="scirp.83558-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Qi, X., de Stefano, V., Hou, F., Ning, Z. and Zhao, J. (2016) Epidemiology, Risk Factors, and in Hospital Mortality of Venous Thromboembolisme in Liver Cirrhosis: A Single Center Retrospective Observational Study. Medical Science Monitor, 22, 969-976. https://doi.org/10.12659/MSM.896153</mixed-citation></ref><ref id="scirp.83558-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Houissa, F., Mouelhi, L., Amouri, N., Salem, M., Bouzaidi, S., Debbeche, R., et al. (2012) Factors Predicting Mortality in Infected Hospitalized Cirrhotics Patients: About 97 Cases. La Tunisie medicale, 90, 807-811.</mixed-citation></ref><ref id="scirp.83558-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Topdagi, O., Okcu, N. and Bilen, N. (2014) The Frequency of Complications and the Etiology of Disease in Patients with Liver Cirrhosis in Erzurum. The Eurasian Journal of Medicine, 46, 110-114. https://doi.org/10.5152/eajm.2014.25</mixed-citation></ref><ref id="scirp.83558-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Goulis, C.E., Arsos, J., Birtsou, G., Nakouti, C., Papadopoulou, S. and Akriviadis, E. (2013) Association between Ratio of Sodium to Potassium in Random Urine Samples and Renal Dysfunction and Mortality in Patients with Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 11, 862-867. https://doi.org/10.1016/j.cgh.2013.02.005</mixed-citation></ref><ref id="scirp.83558-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Onuigbo, W. (2016) The Prevention of Liver Cancer and the Epidemiology of Cirrhosis. Journal of Cancer Prevention and Current Research, 4, 132-133. https://doi.org/10.15406/jcpcr.2016.04.00132</mixed-citation></ref><ref id="scirp.83558-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Xie, Y., Feng, B., Gao, Y. and Wei, L. (2013) Characteristics of Alcoholic Liver Disease and Predictive Factors for Mortality of Patients with Alcoholic Cirrhosis. Hepatobiliary &amp; Pancreatic Diseases International, 12, 594-601. https://doi.org/10.1016/S1499-3872(13)60094-6</mixed-citation></ref><ref id="scirp.83558-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ascione, T., Flumeri, G., Boccia, G. and de Caro, F. (2017) Infections in Patients Affected by Liver Cirrhosis: An Update. Le Infezioni in Medicina, 1, 91-97.</mixed-citation></ref><ref id="scirp.83558-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Da Silva, M., Miozzo, S., Dossin, I., Tovo, C., Branco, F. and de Mattos, A. (2016) Incidence of Hepatocellular Carcinoma in Outpatients with Cirrhosis in Brazil: A 10 Year Retrospective Cohort Study. World Journal of Gastroenterology, 22, 10219-10225. https://doi.org/10.3748/wjg.v22.i46.10219</mixed-citation></ref><ref id="scirp.83558-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bruno, S., Saibeni, S., Bagnardi, V., Vandelli, C., de Luca, M. and Felder, M. (2013) Mortality Risk According to Different Clinical Characteristics of First Episode of Liver Decompensation in Cirrhotic Patients: A Nationwide, Prospective, 3-Year Follow-Up Study in Italy. The American Journal of Gastroenterology, 108, 1112-1122. https://doi.org/10.1038/ajg.2013.110</mixed-citation></ref><ref id="scirp.83558-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kittner, S.V., Sprinzl, J.M., Weinmann, M.F., Wiltink, K.S. and Schattenberg, J.M. (2014) Etiology and Complications of Liver Cirrhosis: Data from a German Centre. Deutsche Medizinische Wochenschrift, 139, 1758-1762.</mixed-citation></ref></ref-list></back></article>